Literature DB >> 20617307

Broad-spectrum drug screening of meconium by liquid chromatography with tandem mass spectrometry and time-of-flight mass spectrometry.

Johanna Ristimaa1, Merja Gergov, Anna Pelander, Erja Halmesmäki, Ilkka Ojanperä.   

Abstract

Analysis of the major drugs of abuse in meconium has been established in clinical practice for detecting fetal exposure to illicit drugs, particularly for the ready availability of the sample and ease of collection from diapers, compared with neonatal hair and urine. Very little is known about the occurrence and detection possibilities of therapeutic and licit drugs in meconium. Meconium specimens (n = 209) were collected in delivery hospitals, from infants of mothers who were suspected to be drug abusers. A targeted analysis method by liquid chromatography-triple quadrupole mass spectrometry (LC-MS/MS) was developed for abused drugs: amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, morphine, codeine, 6-monoacetylmorphine, oxycodone, methadone, tramadol, buprenorphine, and norbuprenorphine. A separate LC-MS/MS method was developed for 11-nor-∆(9)-tetrahydrocannabinol-9-carboxylic acid. A screening method based on LC coupled to time-of-flight MS was applied to a broad spectrum of drugs. As a result, a total of 77 different compounds were found. The main drug findings in meconium were as follows: local anesthetics 82.5% (n = 172), nicotine or its metabolites 61.5% (n = 129), opioids 48.5% (n = 101), stimulants 21.0% (n = 44), hypnotics and sedatives 19.0% (n = 40), antidepressants 18.0% (n = 38), antipsychotics 5.5% (n = 11), and cannabis 3.0% (n = 5). By revealing drugs and metabolites beyond the ordinary scope, the present procedure helps the pediatrician in cases where maternal denial is strong but the infant seems to suffer from typical drug-withdrawal symptoms. Intrapartum drug administration cannot be differentiated from gestational drug use by meconium analysis, which affects the interpretation of oxycodone, tramadol, fentanyl, pethidine, and ephedrine findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20617307     DOI: 10.1007/s00216-010-3942-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  6 in total

1.  The Human Meconium Metabolome and Its Evolution during the First Days of Life.

Authors:  Nihel Bekhti; Florence Castelli; Alain Paris; Blanche Guillon; Christophe Junot; Clémence Moiron; François Fenaille; Karine Adel-Patient
Journal:  Metabolites       Date:  2022-05-05

2.  Metabolic profiles of serum samples from ground glass opacity represent potential diagnostic biomarkers for lung cancer.

Authors:  Jian-Zhong Li; Yuan-Yang Lai; Jian-Yong Sun; Li-Na Guan; Hong-Fei Zhang; Chen Yang; Yue-Feng Ma; Tao Liu; Wen Zhao; Xiao-Long Yan; Shao-Min Li
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 3.  Trends in the application of high-resolution mass spectrometry for human biomonitoring: An analytical primer to studying the environmental chemical space of the human exposome.

Authors:  Syam S Andra; Christine Austin; Dhavalkumar Patel; Georgia Dolios; Mahmoud Awawda; Manish Arora
Journal:  Environ Int       Date:  2017-01-04       Impact factor: 9.621

Review 4.  Screening Pregnant Women and Their Neonates for Illicit Drug Use: Consideration of the Integrated Technical, Medical, Ethical, Legal, and Social Issues.

Authors:  Hayley R Price; Abby C Collier; Tricia E Wright
Journal:  Front Pharmacol       Date:  2018-08-28       Impact factor: 5.810

5.  Determination of Prenatal Substance Exposure Using Meconium and Orbitrap Mass Spectrometry.

Authors:  Atakan Hernandez; Valerie Lacroze; Natalia Doudka; Jenny Becam; Carole Pourriere-Fabiani; Bruno Lacarelle; Caroline Solas; Nicolas Fabresse
Journal:  Toxics       Date:  2022-01-26

6.  Simultaneous determination of 137 drugs of abuse, new psychoactive substances, and novel synthetic opioids in meconium by UHPLC-QTOF.

Authors:  Ángela López-Rabuñal; Daniele Di Corcia; Eleonora Amante; Marta Massano; Angelines Cruz-Landeira; Ana de-Castro-Ríos; Alberto Salomone
Journal:  Anal Bioanal Chem       Date:  2021-07-20       Impact factor: 4.142

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.